Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -63.80
- Piotroski Score 3.00
- Grade Neutral
- Symbol (INFI)
- Company Infinity Pharmaceuticals, Inc.
- Price $0.01
- Changes Percentage (-52.38%)
- Change -$0.01
- Day Low $0.01
- Day High $0.01
- Year High $1.30
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/13/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.44
- Trailing P/E Ratio -0.018181818181818
- Forward P/E Ratio -0.018181818181818
- P/E Growth -0.018181818181818
- Net Income $-43,256,000
Income Statement
Quarterly
Annual
Latest News of INFI
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
INFICON Holding AG (VTX:IFCN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
INFICON Holding's stock has dropped 14% recently, but its high Return on Equity (ROE) of 34% and solid financials indicate potential. With a focus on profitability and growth, the company's performanc...
By Yahoo! Finance | 2 days ago -
All-Star Infielder Ruled Out For Remainder of the MLB Season
Boston Red Sox's Rafael Devers is out for the rest of the 2025 season due to shoulder inflammation. Devers played through pain but struggled, prompting his placement on the injured list. The team call...
By Newsweek | 1 week ago -
JoJo Candidly Admits She's 'Been on Both Sides of the Coin' with Infidelity: 'I've Seen the Cost' (Exclusive)
Joanna "JoJo" Levesque shares her experiences with heartbreak and infidelity in her new memoir, "Over the Influence." Despite past mistakes, she reflects on growth, self-love, and learning from her re...
By PEOPLE.com | 1 week ago
